Entasis Therapeutics

Focused on the discovery and development of breakthrough anti-infective products

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections. A spin-off of AstraZeneca's early anti-infectives portfolio, the company's deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Waltham, Massachusetts